BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25:220-231. [PMID: 29266472 DOI: 10.1111/iju.13512] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Castellan P, Marchioni M, Castellucci R, De Francesco P, Iantorno R, Schips L, Cindolo L. Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations. Ther Clin Risk Manag 2018;14:2341-7. [PMID: 30584309 DOI: 10.2147/TCRM.S159824] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ruiz-Deya G, Matta J, Encarnación-Medina J, Ortiz-Sanchéz C, Dutil J, Putney R, Berglund A, Dhillon J, Kim Y, Park JY. Differential DNA Methylation in Prostate Tumors from Puerto Rican Men. Int J Mol Sci 2021;22:E733. [PMID: 33450964 DOI: 10.3390/ijms22020733] [Reference Citation Analysis]
3 Nevedomskaya E, Baumgart SJ, Haendler B. Recent Advances in Prostate Cancer Treatment and Drug Discovery. Int J Mol Sci 2018;19:E1359. [PMID: 29734647 DOI: 10.3390/ijms19051359] [Cited by in Crossref: 92] [Cited by in F6Publishing: 69] [Article Influence: 30.7] [Reference Citation Analysis]
4 Liao Y, Wu N, Wang K, Wang M, Wang Y, Gao J, Zhong B, Ma F, Wu Y, Jiang N. OTUB1 Promotes Progression and Proliferation of Prostate Cancer via Deubiquitinating and Stabling Cyclin E1. Front Cell Dev Biol 2020;8:617758. [PMID: 33537306 DOI: 10.3389/fcell.2020.617758] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Tian S, Lei Z, Gong Z, Sun Z, Xu D, Piao M. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review. Cancer Cell Int 2020;20:409. [PMID: 32863768 DOI: 10.1186/s12935-020-01508-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
6 Okita K, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Ito A, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study. Clin Genitourin Cancer 2020;18:e103-11. [PMID: 31810867 DOI: 10.1016/j.clgc.2019.09.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
7 Jain HV, Sorribes IC, Handelman SK, Barnaby J, Jackson TL. Standing Variations Modeling Captures Inter-Individual Heterogeneity in a Deterministic Model of Prostate Cancer Response to Combination Therapy. Cancers (Basel) 2021;13:1872. [PMID: 33919753 DOI: 10.3390/cancers13081872] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Shiota M, Ushijima M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Eto M. Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy. Prostate 2019;79:1147-55. [PMID: 31077419 DOI: 10.1002/pros.23828] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Hussain Y, Mirzaei S, Ashrafizadeh M, Zarrabi A, Hushmandi K, Khan H, Daglia M. Quercetin and Its Nano-Scale Delivery Systems in Prostate Cancer Therapy: Paving the Way for Cancer Elimination and Reversing Chemoresistance. Cancers (Basel) 2021;13:1602. [PMID: 33807174 DOI: 10.3390/cancers13071602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hamano I, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer. World J Urol 2019;37:2365-73. [PMID: 30729312 DOI: 10.1007/s00345-019-02664-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
11 Shiota M, Fujimoto N, Higashijima K, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M. Mineralocorticoid receptor signaling affects therapeutic effect of enzalutamide. Prostate 2018. [PMID: 29851126 DOI: 10.1002/pros.23661] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
12 Hu S, Li L, Wu X, Liu Z, Fu A. Post-surgery anxiety and depression in prostate cancer patients: prevalence, longitudinal progression, and their correlations with survival profiles during a 3-year follow-up. Ir J Med Sci 2021. [PMID: 33411223 DOI: 10.1007/s11845-020-02417-x] [Reference Citation Analysis]
13 Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M. Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study. Anticancer Drugs 2020;31:298-303. [PMID: 31913197 DOI: 10.1097/CAD.0000000000000884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Akakura K, Bolton D, Grillo V, Mermod N. Not all prostate cancer is the same - patient perceptions: an Asia-Pacific region study. BJU Int 2020;126 Suppl 1:38-45. [PMID: 32521568 DOI: 10.1111/bju.15129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
15 Yamazaki H, Suzuki G, Masui K, Aibe N, Shimizu D, Kimoto T, Yamada K, Shiraishi T, Fujihara A, Okihara K, Yoshida K, Nakamura S, Okabe H. Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors. Cancers (Basel) 2021;13:3486. [PMID: 34298697 DOI: 10.3390/cancers13143486] [Reference Citation Analysis]
16 Okamoto T, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. Impact of nutritional status on the prognosis of patients with metastatic hormone-naïve prostate cancer: a multicenter retrospective cohort study in Japan. World J Urol 2019;37:1827-35. [PMID: 30511214 DOI: 10.1007/s00345-018-2590-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
17 Fontana F, Raimondi M, Marzagalli M, Audano M, Beretta G, Procacci P, Sartori P, Mitro N, Limonta P. Mitochondrial functional and structural impairment is involved in the antitumor activity of δ-tocotrienol in prostate cancer cells. Free Radic Biol Med 2020;160:376-90. [PMID: 32738396 DOI: 10.1016/j.freeradbiomed.2020.07.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
18 Shiota M, Fujimoto N, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Eto M. Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy. Front Oncol 2018;8:635. [PMID: 30619769 DOI: 10.3389/fonc.2018.00635] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Rutz J, Thaler S, Maxeiner S, Chun FK, Blaheta RA. Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7. Int J Mol Sci 2020;21:E8724. [PMID: 33218199 DOI: 10.3390/ijms21228724] [Reference Citation Analysis]
20 Hatakeyama S, Yoneyama T, Tobisawa Y, Yamamoto H, Ohyama C. Narrative review of urinary glycan biomarkers in prostate cancer. Transl Androl Urol 2021;10:1850-64. [PMID: 33968674 DOI: 10.21037/tau-20-964] [Reference Citation Analysis]
21 Uchimoto T, Komura K, Fujiwara Y, Saito K, Tanda N, Matsunaga T, Ichihashi A, Tsutsumi T, Tsujino T, Yoshikawa Y, Nishimoto Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H. Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer. Med Oncol 2019;37:9. [PMID: 31754918 DOI: 10.1007/s12032-019-1332-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of Taxane Resistance. Cancers (Basel). 2020;12. [PMID: 33182737 DOI: 10.3390/cancers12113323] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
23 Roviello G, Petrioli R, Bonetta A, Conca R, Rodriquenz MG, Aieta M. Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. Invest New Drugs 2018;36:1110-5. [PMID: 30345466 DOI: 10.1007/s10637-018-0685-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
24 Ma X, Guo J, Liu K, Chen L, Liu D, Dong S, Xia J, Long Q, Yue Y, Zhao P, Hu F, Xiao Z, Pan X, Xiao K, Cheng Z, Ke Z, Chen ZS, Zou C. Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing. Mol Cancer 2020;19:147. [PMID: 33032611 DOI: 10.1186/s12943-020-01264-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
25 Kodama H, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Narita T, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer. Clin Genitourin Cancer 2019;17:e1091-8. [PMID: 31575477 DOI: 10.1016/j.clgc.2019.05.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Matsubara N, Suzuki K, Kazama H, Tsukube S, Seto T, Matsuyama H. Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan. J Geriatr Oncol 2020;11:1067-73. [PMID: 32198082 DOI: 10.1016/j.jgo.2020.02.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
27 Grochtdreis T, König HH, Dobruschkin A, von Amsberg G, Dams J. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. PLoS One 2018;13:e0208063. [PMID: 30517165 DOI: 10.1371/journal.pone.0208063] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
28 Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M. Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study. Med Oncol 2019;36. [DOI: 10.1007/s12032-019-1257-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 de Araújo JTC, Duarte JL, Di Filippo LD, Araújo VHS, Carvalho GC, Chorilli M. Nanosystem functionalization strategies for prostate cancer treatment: a review. J Drug Target 2021;29:808-21. [PMID: 33645369 DOI: 10.1080/1061186X.2021.1892121] [Reference Citation Analysis]
30 Matsumoto T, Hatakeyama S, Yoneyama T, Tobisawa Y, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ito H, Nishimura SI, Ohyama C. Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer. Sci Rep 2019;9:16761. [PMID: 31727974 DOI: 10.1038/s41598-019-53384-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
31 Adamaki M, Zoumpourlis V. Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer. Cancers (Basel) 2021;13:E173. [PMID: 33419051 DOI: 10.3390/cancers13020173] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Salgia R, Jolly MK, Dorff T, Lau C, Weninger K, Orban J, Kulkarni P. Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. J Clin Med 2018;7:E156. [PMID: 29914187 DOI: 10.3390/jcm7060156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
33 Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Ibuki N, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Risk stratification for the prediction of overall survival could assist treatment decision-making at diagnosis of castration-resistant prostate cancer: a multicentre collaborative study in Japan. BJU Int 2021;127:212-21. [PMID: 32701219 DOI: 10.1111/bju.15187] [Reference Citation Analysis]
34 Yamashita T, Shiota M, Machidori A, Kobayashi S, Matsumoto T, Monji K, Kashiwagi E, Takeuchi A, Takahashi R, Inokuchi J, Shiga KI, Yokomizo A, Eto M. Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer. Cancer Invest 2021;39:251-6. [PMID: 33393849 DOI: 10.1080/07357907.2020.1871486] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Gómez-Caamaño A, González-San Segundo C, Henríquez I, Maldonado X, Zapatero A; Expert Panel for the Consensus on Management of Castration-Resistant Prostate Cancer 2017, Urological Tumours Working Group (URONCOR), Spanish Society of Radiation Oncology (SEOR). Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology. Clin Transl Oncol 2019;21:420-32. [PMID: 30293231 DOI: 10.1007/s12094-018-1940-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Fontana F, Moretti RM, Raimondi M, Marzagalli M, Beretta G, Procacci P, Sartori P, Montagnani Marelli M, Limonta P. δ-Tocotrienol induces apoptosis, involving endoplasmic reticulum stress and autophagy, and paraptosis in prostate cancer cells. Cell Prolif 2019;52:e12576. [PMID: 30719778 DOI: 10.1111/cpr.12576] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
37 Okamoto S, Shiga T, Tamaki N. Clinical Perspectives of Theranostics. Molecules 2021;26:2232. [PMID: 33924345 DOI: 10.3390/molecules26082232] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 2018;115:E4473-82. [PMID: 29686080 DOI: 10.1073/pnas.1802354115] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 14.3] [Reference Citation Analysis]
39 Adamaki M, Zoumpourlis V. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther 2021;228:107932. [PMID: 34174272 DOI: 10.1016/j.pharmthera.2021.107932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Nishimura K, Nakamori K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Ibuki N, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel) 2021;13:526. [PMID: 33573172 DOI: 10.3390/cancers13030526] [Reference Citation Analysis]
41 Mughees M, Bano F, Wajid S. Mechanism of WASP and WAVE family proteins in the progression of prostate cancer. Protoplasma 2021;258:683-93. [PMID: 33471226 DOI: 10.1007/s00709-021-01608-2] [Reference Citation Analysis]
42 Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. J Clin Invest 2018;128:2979-95. [PMID: 29863497 DOI: 10.1172/JCI96769] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
43 Komura K, Fujiwara Y, Uchimoto T, Saito K, Tanda N, Matsunaga T, Ichihashi A, Tsutsumi T, Tsujino T, Yoshikawa Y, Nishimoto Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H. Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort. J Clin Med 2019;8:E1251. [PMID: 31430900 DOI: 10.3390/jcm8081251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Shiota M, Nakamura M, Yokomizo A, Tomoda T, Sakamoto N, Seki N, Hasegawa S, Yunoki T, Harano M, Kuroiwa K, Eto M. Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study. Cancer Chemother Pharmacol 2019;84:561-6. [DOI: 10.1007/s00280-019-03874-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Cevik O, Acidereli H, Turut FA, Yildirim S, Acilan C. Cabazitaxel exhibits more favorable molecular changes compared to other taxanes in androgen-independent prostate cancer cells. J Biochem Mol Toxicol 2020;:e22542. [PMID: 32578930 DOI: 10.1002/jbt.22542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
46 Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, Tatsugami K, Eto M. Serum testosterone before and during androgen-deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer. Andrologia 2018;50:e13119. [DOI: 10.1111/and.13119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Shiota M, Narita S, Habuchi T, Eto M. Validated prognostic significance of YB-1 genetic variation in metastatic prostate cancer. Pharmacogenomics J 2021;21:102-5. [DOI: 10.1038/s41397-020-00188-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Yang W, Freeman MR, Kyprianou N. Personalization of prostate cancer therapy through phosphoproteomics. Nat Rev Urol 2018;15:483-97. [PMID: 29752463 DOI: 10.1038/s41585-018-0014-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
49 Bhagirath D, Liston M, Akoto T, Lui B, Bensing BA, Sharma A, Saini S. Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients. Sci Rep 2021;11:8279. [PMID: 33859239 DOI: 10.1038/s41598-021-87441-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Hamano I, Okamoto T, Mitsuzuka K, Ito A, Tsuchiya N, Arai Y, Habuchi T, Ohyama C. Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration‐sensitive prostate cancer: A multicenter retrospective study. Int J Urol 2020;27:610-7. [DOI: 10.1111/iju.14258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]